News
Merck KGaA out-licenses M 1095 to MoonLake Immunotherapeutics AG., a proposed treatment for psoriasis.
Merck KGaA has, through one of its subsidiaries, entered into an out-licensing agreement with MoonLake Immunotherapeutics AG, a newly founded clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, for sonelokimab (M 1095).
Merck KGaA has, through one of its subsidiaries, entered into an out-licensing agreement with MoonLake Immunotherapeutics AG, a newly founded clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, for sonelokimab (M 1095).
Sonelokimab is an investigational anti-IL-17 A/F Nanobody, which neutralizes both IL-17A and IL-17F, in patients with moderate to severe chronic plaque-type psoriasis. Currently there are no approved IL-17 A/F nanobodies.
MoonLake Immunotherapeutics will assume full responsibility for the research, development and commercialization of sonelokimab. The company plans to accelerate the development of the asset in multiple inflammatory diseases in dermatology and rheumatology driven by IL1-7A and IL-17F, including psoriatic arthritis (PsA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS) – conditions affecting millions of people worldwide with a large need for improved treatment options. Multiple Phase II trials are expected to be initiated by MoonLake Immunotherapeutics soon.
Condition: Psoriasis
Type: drug
910 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.